semaglutide prediabetes progression to type 2 diabetes trial once a week in adults with overweight or obesity, with or without in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a Semaglutide and Cardiovascular Outcomes in

The net impact on glucose homeostasis is small, but patients with prediabetes or insulin resistance should have fasting glucose and HbA1c checked within 30 days of starting both medications

In a press release, Eli Lilly announced plans to study the drug as a standalone treatment for weight loss

[DOI] [Google Scholar] 97.Hu Y., Xing K., Li X., Sang S., McClements D.J., Chen L., Long J., Jiao A., Xu X., Wang J., et al

However, side effects nausea, vomiting, and diarrhea typically resolve by month 3 for both medications

This equates to approximately 0.73mcg/lb, or about 146mcg for an individual weighing 200lb

Dysaesthesia was also reported at higher rates with the Wegovy 7.2mg injection (22.9%) and appears to be a class-related phenomenon at higher GLP-1 agonist doses